Key Takeaway
Weight loss injections like semaglutide and tirzepatide are FDA-approved and considered safe for most adults when prescribed by a licensed provider and used as directed.
Weight loss injections are FDA-approved and safe when properly prescribed. The STEP-1 trial[1] showed semaglutide caused serious adverse events in only 9.8% of participants compared to 6.2% with placebo. Most side effects are gastrointestinal and temporary. Clinical trials involving over 50,000 participants across multiple studies demonstrate these medications have manageable safety profiles for long-term use.
What the Clinical Evidence Shows
The safety profiles of GLP-1 weight loss injections are among the most studied in modern pharmacology. Semaglutide was evaluated in the STEP trial series with over 10,000 participants, and tirzepatide was tested in the SURMOUNT trials with similarly large cohorts . Both medications showed manageable safety profiles with most side effects being mild to moderate and temporary.
The SELECT cardiovascular outcomes trial further demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20%[3] in overweight or obese adults without diabetes . This finding added significant confidence to the long-term safety of these medications .
Clinical Evidence
GLP-1 receptor agonists have demonstrated exceptional safety records across multiple large-scale trials. The STEP program evaluated semaglutide 2.4mg in over 4,500 participants for up to 104 weeks, showing discontinuation rates due to adverse events of only 7% versus 3.1% for placebo. The SURMOUNT-1 trial[2] tested tirzepatide in 2,539 adults[2], with serious adverse events occurring in 4.8% of participants taking the highest 15mg dose.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
These medications work by mimicking GLP-1, a hormone that regulates blood sugar and slows gastric emptying. Liraglutide 3.0mg was the first approved in 2014, followed by semaglutide in 2021 and tirzepatide in 2022. The cardiovascular outcomes study SELECT tracked 17,604 participants for 33 months, confirming semaglutide reduced major cardiovascular events by 20%[3] while maintaining its established safety profile.
Clinical Evidence
The STEP-1 trial showed 83.5% of participants remained on semaglutide treatment for the full 68-week study period. Pancreatitis occurred in only 0.2% of participants across all GLP-1 trials, and no cases of medullary thyroid carcinoma have been reported in human studies despite theoretical concerns from animal data.
Common Side Effects
Most side effects of weight loss injections are gastrointestinal and tend to decrease over time as your body adjusts. These include:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →
- Nausea: The most commonly reported side effect, affecting roughly 40-45% of users during dose escalation .
- Diarrhea: Reported in about 30% of participants in clinical trials.
- Constipation: Affects approximately 25% of users.
- Vomiting: More common during the initial weeks of treatment or after dose increases.
- Injection site reactions: Mild redness, swelling, or itching at the injection site occurs in a small percentage of users.
These side effects are typically managed through gradual dose escalation, which is why providers start patients on a low dose and increase it over several weeks semaglutide dosing schedule.
Serious but Rare Risks
While uncommon, there are more serious risks associated with GLP-1 weight loss injections that you should be aware of:
- Pancreatitis: Inflammation of the pancreas has been reported in rare cases. Patients should seek immediate medical attention for severe abdominal pain .
- Gallbladder issues: Rapid weight loss from any method can increase the risk of gallstones. GLP-1 medications may add a small additional risk .
- Thyroid concerns: Animal studies showed a link to thyroid C-cell tumors, though this hasn't been confirmed in humans. GLP-1 medications carry a boxed warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma .
Who Should Not Use Weight Loss Injections
Weight loss injections aren't appropriate for everyone. They're generally contraindicated for:
- Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Pregnant or breastfeeding women
- People with a history of severe pancreatitis
- Those with known hypersensitivity to semaglutide or tirzepatide
A thorough medical evaluation before starting treatment is important. Telehealth platforms like FormBlends include a thorough health screening as part of the consultation process.
Are Compounded Injections Safe?
Compounded semaglutide injections, when sourced from licensed 503A or 503B compounding pharmacies, follow strict preparation standards . The active ingredient is the same as in brand-name products. Patients should verify that their provider sources from a properly licensed pharmacy and avoid purchasing injectable medications from unregulated sources compounded vs brand semaglutide.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Are GLP-1 injections safe for long-term use?
Current data supports the safety of semaglutide and tirzepatide for multi-year use. The SELECT trial[3] followed patients for over 3 years and found no unexpected safety signals . But ongoing monitoring by your healthcare provider is recommended .
Do weight loss injections cause muscle loss?
Some lean muscle mass loss can occur with any significant weight loss. Studies show that roughly 25-40% of weight lost on GLP-1 medications may be lean mass . Resistance training and adequate protein intake can help minimize this effect exercise on GLP-1.
Can weight loss injections interact with other medications?
GLP-1 medications can affect the absorption of oral medications because they slow gastric emptying. This is especially relevant for oral contraceptives, antibiotics, and diabetes medications. Always share your full medication list with your prescribing provider .
What makes weight loss injections different from diet pills?
GLP-1 injections work by mimicking a natural hormone that regulates appetite and blood sugar. Unlike older diet pills such as phentermine, which are stimulants with abuse potential, GLP-1 medications have no stimulant properties and aren't considered habit-forming .
How do I know if my weight loss injection source is safe?
Only obtain weight loss injections through a licensed healthcare provider and a verified pharmacy. If using compounded medications, confirm the pharmacy holds a valid state license and operates under FDA-regulated 503A or 503B guidelines. Platforms like FormBlends work exclusively with licensed compounding pharmacies.